Developing our immunology and immuno-oncology portfolio of monoclonal antibodies. chimeric antigen receptor T-cell.
insiders & Institution almost 75% of all the shares.
only 50 million shares & 100 million in cash.
BARDA & NIH supporting phase 3 clinical trial for CV-19.
Positive Interim Phase 3 Data of Lenzilumab in COVID-19 • Interim analysis conducted on the first 165 patients • Estimated 37% more recoveries observed with lenzilumab vs current standard of care • Lenzilumab is tracking to a result that is significantly above and beyond steroids and/or remdesivir • DSMB recommendation to expand the study • Phase 3 trial is significantly de-risked by this data and current study plan • With the current study plan, the trial is 90% powered and has a high probability of success • Total of 515 patients to be enrolled in phase 3 study • EUA filing expected in Q1 2021
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.